A Precision Medicine Initiative for Alzheimer’s disease

the road ahead to biomarker-guided integrative disease modeling

for the Alzheimer Precision Medicine Initiative

Research output: Contribution to journalReview articleResearchpeer-review

39 Citations (Scopus)

Abstract

After intense scientific exploration and more than a decade of failed trials, Alzheimer’s disease (AD) remains a fatal global epidemic. A traditional research and drug development paradigm continues to target heterogeneous late-stage clinically phenotyped patients with single 'magic bullet' drugs. Here, we propose that it is time for a paradigm shift towards the implementation of precision medicine (PM) for enhanced risk screening, detection, treatment, and prevention of AD. The overarching structure of how PM for AD can be achieved will be provided through the convergence of breakthrough technological advances, including big data science, systems biology, genomic sequencing, blood-based biomarkers, integrated disease modeling and P4 medicine. It is hypothesized that deconstructing AD into multiple genetic and biological subsets existing within this heterogeneous target population will provide an effective PM strategy for treating individual patients with the specific agent(s) that are likely to work best based on the specific individual biological make-up. The Alzheimer’s Precision Medicine Initiative (APMI) is an international collaboration of leading interdisciplinary clinicians and scientists devoted towards the implementation of PM in Neurology, Psychiatry and Neuroscience. It is hypothesized that successful realization of PM in AD and other neurodegenerative diseases will result in breakthrough therapies, such as in oncology, with optimized safety profiles, better responder rates and treatment responses, particularly through biomarker-guided early preclinical disease-stage clinical trials.

Original languageEnglish
Pages (from-to)107-118
Number of pages12
JournalClimacteric
Volume20
Issue number2
DOIs
StatePublished - 4 Mar 2017

Fingerprint

Precision Medicine
Alzheimer Disease
Biomarkers
Magic
Systems Biology
Health Services Needs and Demand
Neurology
Neurosciences
Information Systems
Neurodegenerative Diseases
Pharmaceutical Preparations
Psychiatry
Therapeutics
Medicine
Clinical Trials
Safety
Research

Keywords

  • Alzheimer precision medicine initiative
  • Alzheimer’s disease
  • biomarkers
  • integrative disease modeling
  • precision medicine
  • precision medicine initiative
  • systems biology
  • systems medicine

Cite this

for the Alzheimer Precision Medicine Initiative. / A Precision Medicine Initiative for Alzheimer’s disease : the road ahead to biomarker-guided integrative disease modeling. In: Climacteric. 2017 ; Vol. 20, No. 2. pp. 107-118.
@article{3b942d93304a4dffb584bbd98d75569e,
title = "A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling",
abstract = "After intense scientific exploration and more than a decade of failed trials, Alzheimer’s disease (AD) remains a fatal global epidemic. A traditional research and drug development paradigm continues to target heterogeneous late-stage clinically phenotyped patients with single 'magic bullet' drugs. Here, we propose that it is time for a paradigm shift towards the implementation of precision medicine (PM) for enhanced risk screening, detection, treatment, and prevention of AD. The overarching structure of how PM for AD can be achieved will be provided through the convergence of breakthrough technological advances, including big data science, systems biology, genomic sequencing, blood-based biomarkers, integrated disease modeling and P4 medicine. It is hypothesized that deconstructing AD into multiple genetic and biological subsets existing within this heterogeneous target population will provide an effective PM strategy for treating individual patients with the specific agent(s) that are likely to work best based on the specific individual biological make-up. The Alzheimer’s Precision Medicine Initiative (APMI) is an international collaboration of leading interdisciplinary clinicians and scientists devoted towards the implementation of PM in Neurology, Psychiatry and Neuroscience. It is hypothesized that successful realization of PM in AD and other neurodegenerative diseases will result in breakthrough therapies, such as in oncology, with optimized safety profiles, better responder rates and treatment responses, particularly through biomarker-guided early preclinical disease-stage clinical trials.",
keywords = "Alzheimer precision medicine initiative, Alzheimer’s disease, biomarkers, integrative disease modeling, precision medicine, precision medicine initiative, systems biology, systems medicine",
author = "{for the Alzheimer Precision Medicine Initiative} and H. Hampel and O’Bryant, {S. E.} and Sidney O'Bryant and E. Younesi and K. Rojkova and V. Escott-Price and Corvol, {J. C.} and K. Broich and B. Dubois and S. Lista",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/13697137.2017.1287866",
language = "English",
volume = "20",
pages = "107--118",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

A Precision Medicine Initiative for Alzheimer’s disease : the road ahead to biomarker-guided integrative disease modeling. / for the Alzheimer Precision Medicine Initiative.

In: Climacteric, Vol. 20, No. 2, 04.03.2017, p. 107-118.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - A Precision Medicine Initiative for Alzheimer’s disease

T2 - the road ahead to biomarker-guided integrative disease modeling

AU - for the Alzheimer Precision Medicine Initiative

AU - Hampel, H.

AU - O’Bryant, S. E.

AU - O'Bryant, Sidney

AU - Younesi, E.

AU - Rojkova, K.

AU - Escott-Price, V.

AU - Corvol, J. C.

AU - Broich, K.

AU - Dubois, B.

AU - Lista, S.

PY - 2017/3/4

Y1 - 2017/3/4

N2 - After intense scientific exploration and more than a decade of failed trials, Alzheimer’s disease (AD) remains a fatal global epidemic. A traditional research and drug development paradigm continues to target heterogeneous late-stage clinically phenotyped patients with single 'magic bullet' drugs. Here, we propose that it is time for a paradigm shift towards the implementation of precision medicine (PM) for enhanced risk screening, detection, treatment, and prevention of AD. The overarching structure of how PM for AD can be achieved will be provided through the convergence of breakthrough technological advances, including big data science, systems biology, genomic sequencing, blood-based biomarkers, integrated disease modeling and P4 medicine. It is hypothesized that deconstructing AD into multiple genetic and biological subsets existing within this heterogeneous target population will provide an effective PM strategy for treating individual patients with the specific agent(s) that are likely to work best based on the specific individual biological make-up. The Alzheimer’s Precision Medicine Initiative (APMI) is an international collaboration of leading interdisciplinary clinicians and scientists devoted towards the implementation of PM in Neurology, Psychiatry and Neuroscience. It is hypothesized that successful realization of PM in AD and other neurodegenerative diseases will result in breakthrough therapies, such as in oncology, with optimized safety profiles, better responder rates and treatment responses, particularly through biomarker-guided early preclinical disease-stage clinical trials.

AB - After intense scientific exploration and more than a decade of failed trials, Alzheimer’s disease (AD) remains a fatal global epidemic. A traditional research and drug development paradigm continues to target heterogeneous late-stage clinically phenotyped patients with single 'magic bullet' drugs. Here, we propose that it is time for a paradigm shift towards the implementation of precision medicine (PM) for enhanced risk screening, detection, treatment, and prevention of AD. The overarching structure of how PM for AD can be achieved will be provided through the convergence of breakthrough technological advances, including big data science, systems biology, genomic sequencing, blood-based biomarkers, integrated disease modeling and P4 medicine. It is hypothesized that deconstructing AD into multiple genetic and biological subsets existing within this heterogeneous target population will provide an effective PM strategy for treating individual patients with the specific agent(s) that are likely to work best based on the specific individual biological make-up. The Alzheimer’s Precision Medicine Initiative (APMI) is an international collaboration of leading interdisciplinary clinicians and scientists devoted towards the implementation of PM in Neurology, Psychiatry and Neuroscience. It is hypothesized that successful realization of PM in AD and other neurodegenerative diseases will result in breakthrough therapies, such as in oncology, with optimized safety profiles, better responder rates and treatment responses, particularly through biomarker-guided early preclinical disease-stage clinical trials.

KW - Alzheimer precision medicine initiative

KW - Alzheimer’s disease

KW - biomarkers

KW - integrative disease modeling

KW - precision medicine

KW - precision medicine initiative

KW - systems biology

KW - systems medicine

UR - http://www.scopus.com/inward/record.url?scp=85011851560&partnerID=8YFLogxK

U2 - 10.1080/13697137.2017.1287866

DO - 10.1080/13697137.2017.1287866

M3 - Review article

VL - 20

SP - 107

EP - 118

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - 2

ER -